Efficacy, safety and pharmacokinetics of tipranavir + ritonavir alone, or in combination with saquinavir, amprenavir or lopinavir in patients with HIV-1 infections: a randomised controlled trial

Trial Profile

Efficacy, safety and pharmacokinetics of tipranavir + ritonavir alone, or in combination with saquinavir, amprenavir or lopinavir in patients with HIV-1 infections: a randomised controlled trial

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2008

At a glance

  • Drugs Tipranavir (Primary) ; Amprenavir; Lopinavir; Ritonavir; Saquinavir
  • Indications HIV-1 infections
  • Focus Pharmacogenomic; Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top